306 related articles for article (PubMed ID: 33736856)
1. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Nitecki R; Melamed A; Gockley AA; Floyd J; Krause KJ; Coleman RL; Matulonis UA; Giordano SH; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):653-659. PubMed ID: 33736856
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
5. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
6. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
[TBL] [Abstract][Full Text] [Related]
7. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Smith RE; Bryant J; DeCillis A; Anderson S;
J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
Lee JW; Oh H; You JY; Lee ES; Lee JH; Song SE; Lee NK; Jung SP; An JS; Cho KR; Kim CY; Park KH
Eur J Cancer; 2023 Sep; 191():112952. PubMed ID: 37473463
[TBL] [Abstract][Full Text] [Related]
11. Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Matsuo K; Klar M; Mohrbacher AF; Roman LD; Wright JD
Eur J Cancer; 2021 Nov; 157():59-62. PubMed ID: 34487985
[No Abstract] [Full Text] [Related]
12. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Robertson LE; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating MJ
Leukemia; 1994 Dec; 8(12):2047-51. PubMed ID: 7807993
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
[TBL] [Abstract][Full Text] [Related]
15. Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Oliveira JL; Greipp PT; Rangan A; Jatoi A; Nguyen PL
Blood Cancer J; 2022 Jan; 12(1):11. PubMed ID: 35078980
[No Abstract] [Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
17. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
18. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
[TBL] [Abstract][Full Text] [Related]
19. Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis.
Palazzo A; Ciccarese C; Iacovelli R; Cannizzaro MC; Stefani A; Salvatore L; Bria E; Tortora G
ESMO Open; 2023 Apr; 8(2):101154. PubMed ID: 36893518
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
